Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2021 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update

Worldwide Ocaliva® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year Intercept provides initial 2021...
February 23, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
February 19, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conferences

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
February 17, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Appoints Linda Richardson as Chief Commercial Officer

Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept’s Executive Leadership Team NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intercept...
February 11, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 27, 2021 13:35 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Company Statement on Analyst Note

NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 11, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Appoints Jared M. Freedberg as General Counsel and Secretary

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 05, 2021 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
December 10, 2020 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Leadership Transition

Jerry Durso Appointed CEO Effective January 1, 2021;Founder, President and CEO Mark Pruzanski to Continue as Board Member and Advisor NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept...
November 24, 2020 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...